AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ZimVie Completes Acquisition by ARCHIMED, Receives $19.00 per Share in Cash
ByAinvest
Monday, Oct 20, 2025 9:04 am ET1min read
ZimVie has completed its acquisition by ARCHIMED, an investment firm focused on healthcare industries. The deal was announced on July 20, 2025, and ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned. ARCHIMED plans to accelerate ZimVie's growth as a global leader in the dental implant market.
ZimVie Inc. (NASDAQ: ZIMV), a global leader in the dental implant market, has completed its acquisition by ARCHIMED, an investment firm focused exclusively on healthcare industries. The deal, announced on July 20, 2025, has transformed ZimVie into a privately held company, with ARCHIMED acquiring all outstanding ZimVie shares for $19.00 in cash per share, as described in .Under the terms of the acquisition, ZimVie stockholders are entitled to receive $19.00 in cash for each share of ZimVie common stock owned. As a result of the transaction, ZimVie’s common stock no longer trades on the NASDAQ stock exchange. This move signifies a strategic shift for ZimVie, as ARCHIMED aims to accelerate its growth as a global leader in the dental implant market.
André-Michel Ballester, Managing Partner at ARCHIMED, expressed his excitement about the partnership, stating, "ZimVie’s proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED’s mission to support world-class healthcare companies."
Centerview Partners served as the exclusive financial advisor to ZimVie, while Cravath, Swaine & Moore LLP acted as the legal advisor. UBS Investment Bank and Latham & Watkins LLP provided financial and legal advisory services to ARCHIMED, respectively.
ZimVie, headquartered in Palm Beach Gardens, Florida, develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. With facilities around the globe, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life.
ARCHIMED, with offices in Europe, North America, and Asia, is a leading investment firm focused on healthcare industries. With a mix of operational, medical, scientific, and financial expertise, ARCHIMED serves as both a strategic and financial partner to healthcare businesses, managing €8 billion across its various funds.
The acquisition of ZimVie by ARCHIMED marks a significant development in the dental implant market, positioning ZimVie for continued growth and innovation under private ownership.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet